Exagen
XGN
32 hedge funds and large institutions have $61.8M invested in Exagen in 2020 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 15 increasing their positions, 11 reducing their positions, and 7 closing their positions.
36% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 11
0.07% more ownership
Funds ownership: 30.61% → 30.68% (+0.07%)
11% less funds holding
Funds holding: 36 → 32 (-4)
37% less capital invested
Capital invested by funds: $97.7M → $61.8M (-$35.9M)
57% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
+$10.7M |
| 2 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$6.77M |
| 3 |
CAC
Cowen and Company
New York
|
+$4.76M |
| 4 |
BlackRock
New York
|
+$815K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$714K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$14.7M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$12.1M |
| 3 |
Calamos Advisors
Naperville,
Illinois
|
-$1.94M |
| 4 |
EI
EAM Investors
Solana Beach,
California
|
-$808K |
| 5 |
TD Asset Management
Toronto,
Ontario, Canada
|
-$641K |
XGN Hedge Fund Activity: Q1 2020 in Review
32 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in Exagen (XGN) for Q1 2020, worth a combined $61.8M — down 37% from $97.7M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of XGN and 3 opened new positions — a net loss of 4 holders — while 11 trimmed existing stakes and 15 added.
The largest buyer was RTW Investments, adding an estimated $10.7M. The largest seller was Farallon Capital Management, exiting entirely with an estimated $14.7M sold.
- 32 institutional investors held Exagen (XGN) as of Q1 2020, down from 36 in Q4 2019.
- Funds reported $61.8M of Exagen stock for Q1 2020, down 37% quarter-over-quarter.
- 3 funds opened new Exagen positions in Q1 2020 and 7 closed out, a net change of -4 holders.
- The largest Exagen buyer in Q1 2020 was RTW Investments, an estimated $10.7M added.
- The largest Exagen seller in Q1 2020 was Farallon Capital Management, an estimated $14.7M sold.
Based on aggregated 13F filings for Q1 2020.